NASDAQ:RGC Regencell Bioscience (RGC) Stock Price, News & Analysis $27.44 +0.44 (+1.61%) As of 11:16 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Regencell Bioscience Stock (NASDAQ:RGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regencell Bioscience alerts:Sign Up Key Stats Today's Range$27.00▼$27.7050-Day Range$22.68▼$33.7252-Week Range$9.39▼$83.60Volume11,970 shsAverage Volume311,382 shsMarket Capitalization$13.57 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Read More Regencell Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreRGC MarketRank™: Regencell Bioscience scored higher than 8% of companies evaluated by MarketBeat, and ranked 76th out of 80 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRegencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRegencell Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Regencell Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRegencell Bioscience has a P/B Ratio of 2,743.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.16% of the float of Regencell Bioscience has been sold short.Short Interest Ratio / Days to CoverRegencell Bioscience has a short interest ratio ("days to cover") of 7.99.Change versus previous monthShort interest in Regencell Bioscience has recently decreased by 6.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRegencell Bioscience does not currently pay a dividend.Dividend GrowthRegencell Bioscience does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.00 News SentimentRegencell Bioscience has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Regencell Bioscience this week, compared to 3 articles on an average week.Search Interest5 people have searched for RGC on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regencell Bioscience insiders have not sold or bought any company stock.Percentage Held by Institutions0.13% of the stock of Regencell Bioscience is held by institutions.Read more about Regencell Bioscience's insider trading history. Receive RGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regencell Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGC Stock News HeadlinesRGC Deadline Alert: Levi & Korsinsky Reminds Regencell Bioscience Holdings (RGC) Investors of Securities Class Action Deadline on June 23, 20262 hours ago | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers – RGCMay 19 at 4:03 PM | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 20 at 1:00 AM | Brownstone Research (Ad)DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 19 at 12:08 PM | globenewswire.comRegencell Bioscience Raises $20 Million in Registered Direct Offering Led by New Institutional InvestorMay 19 at 9:31 AM | tipranks.comRGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 19 at 9:00 AM | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGCMay 18 at 8:12 PM | globenewswire.comRGC Investors Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud LawsuitMay 18 at 5:18 PM | prnewswire.comSee More Headlines RGC Stock Analysis - Frequently Asked Questions How have RGC shares performed this year? Regencell Bioscience's stock was trading at $21.00 on January 1st, 2026. Since then, RGC shares have increased by 30.6% and is now trading at $27.4340. How were Regencell Bioscience's earnings last quarter? Regencell Bioscience Holdings Limited (NASDAQ:RGC) released its earnings results on Friday, May, 8th. The company reported ($0.01) earnings per share for the quarter. When did Regencell Bioscience's stock split? Shares of Regencell Bioscience split on the morning of Monday, June 16th 2025.The 38-1 split was announced on Monday, June 2nd 2025. The newly issued shares were distributed to shareholders after the market closes on Sunday, June 15th 2025. An investor that had 100 shares of stock prior to the split would have 3,800 shares after the split. When did Regencell Bioscience IPO? Regencell Bioscience (RGC) raised $22 million in an initial public offering on Wednesday, July 14th 2021. The company issued 2,300,000 shares at $8.50-$10.50 per share. Who are Regencell Bioscience's major shareholders? Top institutional shareholders of Regencell Bioscience include Bank of America Corp DE and Amundi. How do I buy shares of Regencell Bioscience? Shares of RGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today5/20/2026Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Medicinal Chemicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RGC Previous SymbolNASDAQ:RGC CIK1829667 WebN/A Phone852 2155 0823Fax852-2155-0853Employees10Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book2,743.50Miscellaneous Outstanding Shares494,490,000Free FloatN/AMarket Cap$13.57 billion OptionableN/A Beta1.88 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:RGC) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersThe Last Time This Market Moved, Early Investors Took NoticeLithium has already had one major run - and now prices are starting to move again. EV adoption and energy stor...i2i Marketing Group, LLC | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayI spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...Decentralized Masters | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
